Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Finished Goods (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Finished Goods for 2 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • For Q4 2025, Finished Goods rose 128.29% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, up 128.29%, while the annual FY2025 figure was $2.0 million, 128.29% up from the prior year.
  • Finished Goods was $2.0 million for Q4 2025 at Day One Biopharmaceuticals, up from $1.1 million in the prior quarter.
  • The five-year high for Finished Goods was $2.0 million in Q4 2025, with the low at $873000.0 in Q4 2024.